HBM Healthcare Investments AG
HBMBF
Other OTC268.61
USD
+28.61
- -
ISIN
CH0012627250
Return %
Stock
S&P500
1Y
29.14
26.84
3Y
26.19
77.03
5Y
-26.61
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Andreas Wicki
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- Bundesplatz 1 Zug Switzerland 6301
- IPO Date
- Jun 23, 2023
- Website
- hbmhealthcare.com
- Similar Companies
- Business
- HBM Healthcare Investments AG (SIX: HBMN; OTC: HBMBF) is a publicly listed Swiss investment company that specializes in healthcare, maintaining a diversified global portfolio of private and public companies focused on biotechnology, medical technology, diagnostics, digital health, services and supplies; its core offerings include direct equity investments in growth-stage firms with proven concepts or clinical milestones, strategic fund commitments in genomics, medical devices, China and India healthcare, and opportunistic public equity positions in small- and mid-cap healthcare stocks, primarily in oncology, immunology, central nervous system disorders, synthetic biology and orphan diseases. Founded in 2001 and headquartered in Zug, Switzerland, the company manages approximately CHF 1.8 billion in net assets as of late 2025, with investments spanning the United States (40-47%), Europe (23-33%), Asia (27-30%) including China and India, and a balanced asset allocation of roughly 30% private equity, 50% public equity (half former privates), 8-10% funds, and 8% cash. HBM Healthcare Investments AG employs a permanent capital structure for flexibility in follow-on financings, board representation in key privates, and active value creation toward IPOs or trade sales, targeting 3-5% annual dividend yields alongside share buybacks. The company's largest holdings feature Swixx BioPharma (12.8%, full representation services for biopharma in CEE, CIS, Latam and MENAT with EUR 1 billion+ sales), Cathay Biotech (11.3%, profitable synthetic biology for bio-based chemicals), Merus (3.7%, bispecific oncology antibodies including petosemtamab), Argenx (3.2%, Vyvgart for autoimmune diseases), Harmony Biosciences (2.6%, Wakix for narcolepsy), Neurelis (2.5%, Valtoco nasal spray for epilepsy), Mineralys Therapeutics (1.9%, lorundrostat for hypertension), Upstream Bio (1.8%, verekitug for inflammatory diseases), Zymeworks (1.7%) and ArriVent Biopharma (1.6%); private standouts include NiKang Therapeutics (oncology), Nuance Biotech (China specialty pharma), Tata 1mg (India online pharmacy) and Shape Memory Medical (embolization devices), with over 70 successful exits via IPOs and trade sales validating the strategy. Recent developments include portfolio company acquisitions driving NAV growth, such as Genmab's USD 8 billion purchase of Merus (41% premium, Q3 2025), Sanofi's up-to USD 1.9 billion asset deal for Dren Bio's DR-0201 (closed Q2 2025, CHF 8.70 NAV uplift), Johnson & Johnson's USD 1.3 billion buy of Yellow Jersey Therapeutics (2024, CHF 59 million gain), Roche's up-to USD 3.5 billion offer for 89Bio, and SERB Pharma's USD 412 million acquisition of Y-mAbs Therapeutics (2025); Swixx BioPharma expanded via a multi-regional CNS portfolio deal with Lundbeck (2025) and Biopas acquisition (2024), boosting sales toward EUR 1.2 billion, while Sai Life Sciences' INR 30.4 billion IPO (Dec 2024) yielded HBM 12.4x multiples on unrealized gains. HBM completed its 2022 share buyback (252,610 shares, CHF 46.3 million) and launched a new 3-year program for up to 10% of shares (July 2025), alongside CHF 7.50 per share distributions (4.1% yield); the 2025/2026 half-year reported CHF 96 million profit (NAV +6.1% to CHF 251.78 despite CHF appreciation), with new investments in Immuneering, UniQure, Scholar Rock and OneSource Speciality Pharma.